Print this page    •   Back to Web version of article

STEP Perspective
Summer 1998

Contents

Letter from the Editor


Most of this issue is dedicated to bringing you the highlights that came out of the 5th Conference on Retroviruses and Opportunistic Infections. Conferences like these are vitally important and bring together some of the best minds working to stop this epidemic. Overall, this conference had the feeling of "staying the course" or cautious optimism. Although there were no monumental new discoveries, there was some great news. Studies continue to show a decline in the death rate due to AIDS and a slow steady progress towards making this disease more manageable and less life threatening.

As we learn more about antivirals, more questions arise about how and if we can restore the immune system. In this issue we continue our investigation of researchers studying immune restoration with an interview with Dr. Ronald Moss of the Immune Response Corporation. The immune restoration drug in development here shows great promise and has a unique approach on how it attempts to rebuild the immune system.

With summer weather heating up we take a look at managing body weight and preventing wasting with BIA testing. Our story on Bioelectrical Impedance Analysis (BIA) explains this new test, why it is important, and how to use it to monitor your health and catch wasting syndrome early. In our Just For Women Column, we explore the effects of HIV drugs on oral contraceptives, and we get a personal story of what it is like to be a woman in a rural community trying to remain compliant.


Rebuilding the Immune System

Promising New Therapy Uses the HIV Virus Itself to Awaken the Damaged Immune System

In this article, the second interview in our series exploring immune restoration, we look at a different approach to immune-based therapies. In these therapies, the outer shell of the HIV-virus is removed and only the inner proteins of HIV are used. These proteins act to stimulate the memory cells that create more of the HIV-fighting T-cells that were killed off early in the disease process. These concepts originated with Dr. Jonas Salk in the 1980s, and have been both praised and dismissed since then.

Today, Salk's concepts are gaining more attention and their development is continuing under the direction of Ronald Moss, MD, Senior Director of Medical and Scientific Affairs at the Immune Response Corporation.


STEP: Do you consider Remune to be an immune-based therapy rather than a vaccine?

Dr. Moss: Absolutely. I think the misnomer was referring to this immunogen as a vaccine; it's not a therapeutic vaccine. The term vaccine implies a preventative type of a procedure -- that one could give a particular type of injection and prevent a disease. We are [also] working on the area of preventative AIDS vaccine, but Remune itself is a way of stimulating the memory response of the immune system.

The goal is to stimulate the body into producing the special T-cells that early in the infection period fight and kill HIV. We know that early in the disease there is a progressive loss of the ability of the immune system to recognize HIV. Early in the infection period the immune system does battle the virus through the cell-mediated arm of the immune system. This is the arm that includes T-cells, cytotoxic T-cells [T-cells that directly kill HIV-infected CD4 lymphocytes], and other various factors that have direct activity against the virus. So the body initially intends to fight the virus using these and eventually the virus wins and overcomes the immune system. But the fact that the immune system has already had an initial battle with the virus means there are memory cells in the immune system that can be re-stimulated to re-emerge and battle the virus again.

The excitement now about Remune is how it can work in conjunction with combination therapy to possibly create immune systems in people that can look like the immune system of a non-progressor. Current drug combinations can lower viral loads to very small levels yet leave these memory cells intact. Remune can stimulate the body into producing more of these fighting cells that can then attack the already depleted virus. I believe that data will soon show that individuals immunized on drug therapy with Remune will have immune systems that look very much like a non-progressor immunologically. The work by Dr. Bruce Walker and others proves that the immune system can be stimulated to control the virus under the proper conditions. And, clearly the proper conditions are in individuals taking highly active antiretroviral therapy [HAART].

STEP: So there's been some confusion around the terminology of vaccines and immune-based therapies, and people not making the distinction?

Dr. Moss: I think so. I think there's no doubt about it that it's a struggle. We've begun using the terminology "immune-based therapy" because I think that is the most appropriate word. You talk to Dr. Walker and he's still using the word therapeutic vaccine. The other difference between Remune and a preventative vaccine is that with Remune we are re-stimulating the memory response in an infected person. So, immunizations have to continue in order to keep this immune response up and that is very different from a preventative vaccine. I think we really do have to try to change that terminology a great deal.

STEP: In Dr. Walker's work he was able to show that long-term non-progressors maintain high levels of these HIV-specific memory cells and that rapid progressors lost them very quickly.

Dr. Moss: I would argue with that -- some studies show that there isn't really a loss of these cells. They're just overwhelmed by virus and not able to function properly. I'm actually more optimistic than Dr. Walker. With proper immune stimulation we can get some sort of anti-HIV response in individuals who have had evidence of clinical progression so long that they're on some sort of drug therapy that's controlling the new virus replication.

STEP: Would it be fair to say then that Remune would be a therapy that, if it works well, will allow the immune system to go back and fight the fight like it would if it were healthy?

Dr. Moss: Exactly. With some of the earlier studies there were a lot of questions including why we were seeing vigorous immune responses in some individuals and not in others. Now with the ability to control the virus we're seeing a much more consistent vigorous immune response in Remune-treated individuals. So it may be that Remune can help turn the clock back in terms of progression just like the drugs (HAART) have turned the clock back.

The other issues about anti-HIV drugs and Remune is that there are certain reservoirs of virus that the drugs can not reach and kill. If the goal is total eradication of HIV, one probably will get closer to that goal by using therapies like Remune. We believe that this type of therapy would be able to capture some of the reservoirs left over from the drug therapies. In one sense it may allow people to be on a particular drug regimen for a longer period of time. That's one of the many things that we're testing in our studies. In my clinic switching drug therapies is a constant battle. If you were able to stimulate the immune system to the point where you could keep the individual on a fairly well tolerated and simple drug regimen for a longer period of time, that would be a significant contribution for better care for patients.

STEP: I know that there were concerns expressed 3 or 4 years ago about Remune -- that you didn't see a strong antibody response. Could you address why you don't see that type of response with Remune?

Dr. Moss: Sure. The original concept about HIV-infected individuals was that one needed to develop strong antibody responses, particularly neutralizing antibodies. And there were a number of immunogens put together to invoke those neutralizing antibodies. The so-called envelope immunogens [vaccines which used the outer shell or envelope of the HIV cell] developed some very strong neutralizing antibody responses. But what they found later was that these antibody responses inhibited only laboratory strains of the virus but did not inhibit the patient's own virus. [So] the thought that antibody was the essential part of controlling the disease has somewhat lost favor. Dr. Salk all along thought that the cell-mediated arm of the immune system was much more important. As I mentioned earlier, that's the arm that is involved with the cytotoxic T-cells, cytokines, chemokines, and of course the virus itself. So he devised an immunogen to enhance the cytotoxic T-cells and the cell-mediated arm of the immune system. This has been validated recently by the data from Dr. Bruce Walker's study looking at cell-mediated immunity.

We know, and Dr. Salk knew, that different doses of an immunogen could cause the body to produce different types of antibodies. We chose a regimen that would cause the body to produce primarily the HIV-specific killer T-cells, or cell-mediated immunity. And I think this is really the important arm in controlling this disease.

STEP: You talked about Dr. Salk and a lot of people probably won't know his role with Remune. Do you want to cover that?

Dr. Moss: Well, in the last years of his life Jonas Salk was obsessed with HIV infection and ways of dealing with it. He was the one who developed the concept of immune-based therapy. At the time (in 1987, prior to drug therapies) we didn't know a lot about the immunology of AIDS. But he saw that from the time an individual was infected to the time symptoms develop was about 10 years. He rationalized that there must be some kind of immune response to the virus that is different from a fatal disease like meningitis where one would succumb within 24 hours. So he wanted to parallel what was going on during the asymptomatic period. His thinking was that the immune system needed something to stimulate its memory, like an immunogen in slightly altered form. So, it was [from] this conception that Remune was developed.

At the time there was a lot of interest in envelope immunogens. The NIH [National Institutes of Health] was quite sure that immunization with the outside of the virus, both for preventative and therapeutic purposes, was going to prevent the disease. The NIH poured a lot of funding into this arena and there was not a lot interest in Dr. Salk's suggestion, and he published this in 1987 in a review article. So he ended up hooking up with the Immune Response Corporation to develop this [idea]. Until his death Dr. Salk was intimately involved with the day-to-day science of the program. I was very fortunate to work with him.

STEP: So you're saying that Remune will actually help the body to create more of the HIV-specific T-cells?

Dr. Moss: Yes. I'm saying that we do have data. We will be showing exciting new data from a placebo control study comparing a group using Remune plus drugs, to a group using drugs alone. Both groups had very good drops in virus, but the Remune plus drug group had dramatic increases in HIV-specific immune responses compared to the drug alone group, which during the study was a flat line. With the current drugs we are seeing a greater magnitude in the immune responses after the immunization with Remune. The drugs are allowing the immune system to digest immunization to a greater extent than when the virus was still there without drug therapy.

STEP: Can you summarize in just a couple of sentences what the major benefits of Remune are right now?

Dr. Moss: Well, I can't let the cat out of the bag, but there will be new, exciting data in Geneva, presented on at a satellite symposium. With Remune the goal is to generate HIV-specific T-cells that kill the virus,[but] that are lost very early in the disease. There's going to be a study out by Dr. Gallo looking at the mycobacterium avium complex (MAC) cohort where he looked at our HIV antigens in Remune.

Essentially, when he looks at healthy people there are some HIV-specific responses there, but when he looks at people with full-blown AIDS the HIV-specific responses are completely gone. So the goal of a therapy like Remune is to stimulate those responses, to mimic the responses seen in non-progressors. The goal with Remune is to bring some sort of additional immune surveillance that may not and is not brought back by drug therapy alone. The drug therapy alone, as I mentioned, is extremely good at dropping the viral load and, you'll see in Geneva, that we have data showing that the drugs alone are not bringing back the HIV-specific responses.

The other way that Remune might be shown to have a benefit is its ability to keep individuals on a particular drug regimen for a longer period of time. Some sort of delay in resistance might afford patients to be on a drug for a longer period of time because Remune itself is getting some sort of immune surveillance against the virus. This is the way that I envision Remune to potentially provide some clinical benefit in the future.

STEP: How is Remune given, and are there side effects?

Dr. Moss: It is a fairly simple type of treatment. It's an intra-muscular injection in the arm given every 3 months, so adherence and intolerability are not really a problem. The main side effect we see has been local injection site reaction, similar to what one sees in a pediatric vaccine -- redness and swelling and warmth at the injection site, which resolves within 24 hours.

STEP: Based on the fact that there are no agreed-upon surrogate markers, how do you think we're going to be able to tell if immune-based therapies are really working?

Dr. Moss: We are working on a couple of things. As I mentioned, we need to validate immune function markers in the same [way] that RNA was validated and I think Dr. Gallo's (MAC) study is the first of many studies that will be looking at this question. We really have to get the assistance and help of many different diagnostic companies. That's number one. Number two is we have a skin test we're using in large trials. We know that it indicates some sort of response against the virus. We really need to help a diagnostic company get into this area.

STEP: If I'm on a hot regimen that was successful and decided to add Remune and I don't have these types of surrogate marker tests available, what type of things would I look for to decide whether the therapy was beneficial?

Dr. Moss: I think that's a difficult question. Most things would be subjective. You would look for your viral load to be stable for a long period of time. You wouldn't be able to tease out whether or not that would be due to Remune or the drugs or the combination of the two. You would look at all of your clinical parameters. We've seen weight increases in Remune patients. But I don't think any of those parameters would be able to differentiate Remune from the drugs unless you had a marker of HIV-specific immune function.

But, as I said earlier, data that will be presented in Geneva look towards the concept that the drugs alone may have some effect on the non-specific immune system but have very little impact on HIV-specific immune function. So that would be a dilemma. But we do have folks who have been on Remune for over 10 years [and] who continue to take it and believe it. It is just anecdotal, and we don't know for sure whether Remune is responsible for keeping them healthy. We do see some immunological changes in them. We need the skin testing or some other HIV-specific test and I think it would be great for the community to try to get some of the diagnostic companies involved in this arena as they did with RNA testing.

STEP: Is Remune available now to people?

Dr. Moss: We have what's called an expanded access program. We haven't really publicized it a great deal but it's out there. And I imagine there will be increasing interest after Geneva. We will have to decide internally what to do about the expanded access program at that point. It's available and there are multiple studies still on-going. We will be starting, for example, a study with Dr. Walker that will be enrolling patients. We will be starting a primary infections study with Eric Darr in Los Angeles and we are open to hearing from investigators and the community about new studies that they'd like to see with Remune as well.

STEP: Is there a certain type of patient that you would recommend to get on Remune? In terms of somebody who's HIV-positive but asymptomatic with a nondetectable viral load versus somebody with full-blown AIDS?

Dr. Moss: I have a theory on this that's not very scientific. I think there is two types of individuals. One is an individual who may not want to go on drug therapy very early on and Remune might be something to go on before one really needs drug therapy. Before viral load is detectable, for example.

The other type of patient who would benefit from Remune is someone doing well on drugs, who has a viral load no greater than 100,000. Controlling the virus somewhat is probably important for Remune to work properly. I'm not saying that one needs absolute control of virus to use Remune. I think that there needs to be some control of virus before immunization with Remune to really see the true benefit immunologically. So I would not recommend someone with 500,000 copies trying Remune, but perhaps for someone under 100,000 copies it would be worthwhile. And clearly people with a very low viral load would probably get the strongest immune responses entering immunization with Remune.

STEP: There are some current trials looking at the possibility of maintenance therapy where you hit somebody with three or four drugs early on and once you get the virus down, you see if you can maintain that with a two-drug regimen. Have you thought about trials with Remune in a situation where people could scale back their HAART regimen to a maintenance regimen?

Dr. Moss: We haven't really thought about that completely. It's obviously a good concept though. I would think that would make sense. The other possibility is looking at adding another antiretroviral and seeing if Remune has an impact. I think that those are all good ways of looking at it. I think if Remune works there's a lot of possibilities to tease this apart further.

STEP: As a last question, can you give our readers an idea of how long the vaccine's been studied and then talk about the clinical endpoint study that's going to be coming to an end probably in March of 1999?

Dr. Moss: The vaccine has been around since 1987 so we have individuals who have continually gotten immunized since 1987 from those early studies here in California. We crept our way up the ladder and did our Phase I and Phase II studies. And this always has been controversial -- number one, because Dr. Salk was the person who initiated this, and secondly, we came up at a time when many of the envelope vaccines supported by the government were failing. And I think people threw Remune into the same boat as some of the envelope vaccines. I hope that I've expressed to you that this is really a different animal.

This particular immunogen has the conserved parts of the virus, the parts of the virus that are same regardless of what type of virus one is dealing with. We have shown scientifically that we can immunize patients with Remune and they can develop immune responses to different types of HIV antigens. This was never shown for envelope vaccines because they were always showing good responses to their own antigens but never to other viruses. So Remune is very different than the envelope vaccine.

We continued to move on to two different types of studies. One was a surrogate marker study that you'll hear about in Geneva. There are multiple studies going on in Europe and Asia [now] , and South America shortly, and 2 years ago we initiated one of the largest studies ever conducted in the United States. It's a Phase III clinical endpoint study and we have another year to go. It's the only immune-based therapy that was given the green light by the FDA to do a Phase III study for infected individuals.

We feel confident that we are in the right place at the right time. The irony is that advances in drug therapy will increase the ability to show clinical benefit using something like Remune in combination with an immune system that has better control of its virus. We're fairly close and not overly confident, but we believe that the data will tell the story in the long run.


Coverage of the 5th Conference on Retroviruses and Opportunistic Infections

All summaries by Jeffrey Schouten, MD, Chairman, Scientific Review Committee, STEP, unless otherwise noted.


Opening Session Highlights

Presenter -- Dr. Ashely Haase

Dr. Ashley Haase delivered both good and bad news with his data showing that lymph nodes remain the main reservoir of HIV, even after highly active antiretroviral therapy (HAART) therapy. The lymph nodes contain lymphocytes with no viral RNA, but with viral DNA incorporated into their genetic code.

Referring to the M (or "mystery") cells that harbor HIV DNA, Dr. Haase stated that these cells remain in the lymph nodes even after 2 years of no detectable viral load in the blood on HAART. Thus, the realization over the last 6 months is that HAART will probably not lead to viral eradication. On a more positive note, he noted that there is evidence of rehabilitation and rebuilding of the immune system on HAART, and that even after only 6 months of HAART, there is evidence of restoration of normal lymph node architecture.


Keynote Lecture

Presenter -- Dr. David Baltimore

Dr. David Baltimore delivered the Keynote Lecture, discussing the challenges of making an HIV vaccine. He is head of the federal government's AIDS Vaccine Research Committee (AVRC). Vaccines work by generating antibodies, generating cellular immunity (cytotoxic T-lymphocytes [CTL]), and/or some undefined third non-immunologic mechanism. He suggested that the third process could be that a non-pathogenic virus could be developed to occupy a space needed by HIV to establish infection, thus blocking infection by HIV. He noted that it is rare for a person to become infected with a second strain of HIV once they are infected with one strain of HIV.

Dr. Baltimore believes there is total commitment on the part of the federal government to expend whatever resources are needed to develop an AIDS vaccine. The vaccine need not necessarily prevent HIV infection, but rather prevent disease caused by HIV. It must be very safe, well tolerated, durable, transportable, easily administered, and protect against different routes of infection, such as via mucus membranes or via injection.

Dr. Baltimore noted that the Macaque monkey can be completely protected by live simian immunodeficiency virus (SIV), which is deficient in a regulatory gene (the NEF gene). It has been shown that a few people in the United States and Australia have been infected with a NEF-deficient strain of HIV and they have normal immune systems after long-term infection.

Dr. Baltimore reviewed the limitations of antibody vaccines, which do not immunize against wild type (real world) virus. There is cell-mediated killing of HIV-infected lymphocytes. The half-life of HIV-infected T-cells is about 2 to 3 days. However, one of the challenges is to figure out how HIV prevents CTL from killing infected cells. Dr. Baltimore is not in favor of giving a live-attenuated HIV virus to human volunteers, and feels that there needs to be a much better understanding of how HIV can be prevented by the various techniques discussed above.


Session 2: State-of-the-Art Lecture Monitoring the Epidemic of HIV/AIDS in the United States

Presenter -- Dr. Kevin Decock, CDC

Dr. Decock reviewed the epidemiology of HIV/AIDS in the United States. Transmission is closely linked the following factors: Socioeconomic status Substance abuse Exchange of drugs for sex Presence of other STDs Of concern were data from public health clinics that showed HIV-positive persons had a relatively high incidence of sexually transmitted diseases (STDs). STDs increase the risk of HIV transmission by 4- to 5-fold. He emphasized that better control of substance abuse and STDs is critical to controlling the spread of HIV. In 1997, there was a 12 percent decrease in incidence of AIDS compared to 1996. Dr. Decock presented a slide that showed the flow of HIV into one bucket, representing HIV cases, which then flowed into a second bucket, AIDS cases, which then flowed out of the second bucket to account for AIDS deaths.

With decreasing AIDS cases, the number of people in the first bucket, HIV cases, is increasing. This was his justification for the CDC's call (a "technical opinion") for mandatory names reporting.

He noted that 31 states require HIV names reporting, but these states represent only one-third of all HIV cases. He said that there have been no breaches of confidentiality. (NOTE from the reviewer: Apparently, Dr. Decock is not aware of the major breach in Florida. Nor did he even mention the option of using unique identifiers to gather the same data, which would better protect confidentiality and while not discouraging HIV testing.)


Session 7: Immunopathogenesis Symposium

This session reviewed data concerning the quality of the increased number of T-cells in people on HAART. The big question is whether or not the increased T-cells are only memory cells (already programmed to respond to one antigen, or pathologic organism), or are there increases in naïve T-cells (new T-cells capable to responding to a new pathogen, or disease-causing organism). The good news is that there appears to be increases in both memory T-cells and naive T-cells in people on HAART therapy. The memory cells increase in the first few weeks, then plateau (usually at 300 to 400), while the naive cells slowly increase over several months.


Session 9: Chemokine Receptor Symposium

Presenter -- Dr. Moore

There was a great deal of detailed biochemistry presented about the chemokines. Chemokines are secreted by certain cells in the immune systems, and allow HIV to enter a healthy cell and infect it. The chemokine receptors appear to be necessary for the HIV to bind to the CD-4 lymphocyte and infect the cell. Generally, the CXCR4 receptor is on the T-cell, and the CCR5 receptor is on memory cells.

The chemokines became a major focus of HIV research in the last 2 years when they were identified as important co-receptors allowing for HIV entry into the cell. Additionally, some people have a genetic mutation causing them to not produce CCR5 receptors and are therefore immune to HIV infection. Also, people who lack one but not both genes for the CCR5 receptor (called the heterozygous CCR population) appear to have a slower rate of disease progression.

Dr. Moore explained why there have been some apparently conflicting data concerning the rate of progression of HIV disease in the heterozygous CCR5 population. Studies that have followed progression from time of diagnosis have shown a slower rate of progression among the heterozygous CCR5 population. However, studies that look at the number of heterozygous people at one time during the course of the infection, not at the initial time of infection, have not shown a difference in rate of infection. This is because the effect on disease progression is not that strong, so the effect will only be apparent in patients followed from the time of diagnosis.


Session 5: Antiretroviral Chemotherapy I Slide Session

Summary by Brian Coppedge, Treatment Information Specialist, STEP

The first slide session provided the first look at data on antiretroviral agents. The three following presentations focused on combinations that would no longer be recommended when following the new treatment guidelines. These guidelines could provide information that would be useful when choosing two reverse transcriptase inhibitor (RTI) drugs to be used as part of a triple combination.

Daniel Kuritzkes, MD, of the University of Colorado, presented data from the ACTG 306 study. When this trial began (December 1995) there was some question whether 3TC had a unique relationship with AZT, or if the same benefit could be seen when 3TC was added to ddI or d4T. To determine this, people were placed into random groups. These groups then received d4T alone, a combination of d4T/3TC, AZT/3TC, ddI alone, or a combination of ddI/3TC or AZT/ 3TC. At 48 weeks, the results suggest that the combination of 3TC and d4T is at least as effective as 3TC and AZT. It was also shown that d4T/3TC was more potent than d4T monotherapy (big surprise -- I think we have known that for a while).

The study also showed that when 3TC is added to ddI, the combination is not more potent than ddI monotherapy. Dr. Kuritzkes made a point of stating that 3TC can be combined with either d4T or AZT but that the two drugs should be used as part of a combination that includes a protease inhibitor.

Having shown that 3TC can be used successfully with d4T, researchers have been inquiring whether d4T can be used successfully with AZT. Many people have been under the impression that d4T and AZT should not be used in a combination because they were antagonistic (when taken together, there is less benefit than when either is taken alone).

Dr. Havlir presented the results of the ACTG 290 study, which investigated whether AZT and d4T were antagonistic. After looking at 144 people (all of whom had been on AZT before) who were randomized into groups receiving a combination of AZT/d4T, d4T alone, a combination of AZT/ddI, or ddI alone, the investigators came to three conclusions. First, AZT/d4T should not be used in combinations because AZT/d4T does not have a more potent antiviral effect than d4T monotherapy, and AZT/d4T is associated with a drop in CD4 cells in people who have taken AZT before. Second, ddI produces a greater level of viral suppression than d4T when taken by people who have used AZT previously. Third, the combination of AZT/ddI in people who are AZT-experienced had no more benefit than ddI monotherapy.

Next was a presentation that actually looked at a new compound, abacavir (1592, an RTI), in combination with five different protease inhibitors. John Mellors, MD, from the University of Pittsburgh, presented the results of a study that randomized 80 people into groups that received abacavir (300mg every 12 hours) in combination with either indinavir (Crixivan), ritonavir (Norvir), saquinavir (Fortavase), nelfinavir (Viracept) or the new protease inhibitor, 141W94. The drugs performed well, with 50 to 85 percent of the participants seeing their viral load reduced to below 400 copies at 16 weeks, and 40 to 70 percent to below 50 copies at 16 weeks. (Dr. Mellors noted that the group receiving saquinavir produced inferior results). Some participants (2 to 5 percent) developed a rash from abacavir that was seen 3 to 42 days after beginning therapy. It is important not to re-start abacavir after discontinuing the drug (rechallenging) because of the development of a rash. Five people were hospitalized and one person died after they were re-challenged with abacavir.

Finally, what does the future of dual protease therapy look like? Dr. Eron from the University of North Carolina presented a humorous and informative piece on dual protease therapy that evaluated amprenavir (141W94) with one of three other protease inhibitors: indinavir, saquinavir, and nelfinavir. Although the data presented was only for a very small study group (16 people) the results helped to provide an idea of which combinations should be studied in larger trials. After 16 weeks, all participants had viral loads below 400 copies.

Dr. Eron concluded by stating that the regimens were well tolerated and this study suggests that dual protease inhibitor therapy is a viable alternative to triple combinations. He noted that it is perhaps a bit too early to compare these regimens to triple therapy, considering the short study period and the fact that no participants were tested using ultra-sensitive tests that detect viral loads below 400 copies.


Studies of HIV Infection in Women

Donna Rochon, Editor, RITA! The Center for AIDS, Houston, TX

A welcome addition to the hundreds of presentations and posters was a varied assortment that addressed treatment issues specific to women. Although a few studies presented data on trials designed to assess the effect of anti-HIV drugs on women, most of the research being conducted continues to look at the effect of antiretroviral or prophylactic (preventative) therapy on pregnant women and their newborns.

While methods for reducing the risk of transmission from the mother to her newborn are still an extremely important and essential area of investigation, it would be refreshing if researchers took a more serious interest in improving the health of HIV-positive women, regardless of their childbearing capabilities.

The Women's Interagency HIV Study (WIHS) is one of the few large-scale studies that focuses on women's health, and several pharmaceutical companies, to their credit, are beginning to enroll women in trials to evaluate drug efficacy in women. Several key posters and presentations are highlighted below.


Session 8: AIDS Malignancies. In a symposium on AIDS malignancies, Dr. Lowy emphasized that cervical cancer is the number two cancer among women worldwide. This high incidence of cervical cancer appears to be directly related to infection with human papillomavirus (HPV), a very common sexually transmitted disease (STD).

Researchers have found that HPV DNA is found in almost all cases of cervical cancer. In women with HIV infection, cervical HPV is more persistent than in HIV-negative women, and there is a higher proportion of abnormal new growth in cervical intraepithelial tissues (neoplasia) in HIV-positive women. Further, increased rates of progression to severe abnormal growth (dysplasia) have been noted in women with HIV infection, with lower CD4+ cell levels associated with greater risk. While CD4+ cell count was found to be an inconsistent predictor of HPV disease, plasma HIV RNA levels greater than 10,000 copies posed a greater risk for HPV that causes tumors.

Quantitative HIV-1 RNA and Other Factors Associated with Survival in the Women's Interagency HIV Study (WIHS). The objective of this ongoing study is to determine factors associated with survival in HIV-positive women. To date, data has been analyzed for 2,058 women who are HIV-positive and 567 HIV-uninfected women recruited in five cities in the United States between October 1994 and October 1995. Clinical, virologic, and immunologic evaluations were performed every 6 months. There were 242 deaths in the 1,890 HIV-positive women, with low CD4+ cell count and high viral load the contributing factors, as well as the occurrence of an AIDS-defining illness. There was a trend toward poorer survival in older participants, but survival was not associated with race, ethnicity or route of HIV exposure. Thus, women with low CD4 counts and viral loads greater than 500,000 had the greatest risk of death.


Benefits of Vitamin B

Summaries by Paul Simmons, RN, The Center for AIDS, Houston, TX

In a presentation that is sure to have advocates of complementary therapy saying "I told you so," Andrew Kanter of the WITS Medical School, Johannesburg, South Africa, and colleagues presented fascinating data on the role of multivitamins and B-complex vitamins in delaying progression to AIDS and death. The data presented here are drawn from a retrospective chart review of over 2,100 HIV-positive individuals treated at the Johannesburg General Hospital HIV Clinic.

The median time from infection to full-blown AIDS in patients taking a multivitamin was 71 weeks, compared to 33 weeks for those not taking a multivitamin. Even more striking was the AIDS-free time associated with a B-complex vitamin. The median time to progression for those taking vitamin B-complex was 152 weeks, compared to 32 weeks among those who didn't. The data were less impressive but still important for those with a diagnosis of AIDS.

Median survival among AIDS patients taking vitamin B-complex was 62 weeks, compared to 42.5 weeks in those who did not. These results did not change even after controlling for CD4 count and antiretroviral therapy.

Since this data was obtained from a retrospective chart review and not a controlled clinical trial, it is possible that other intervening variables influenced the results. For example, the vitamin takers may have been individuals who generally took better care of their health than the non-vitamin takers. I asked Kanter about this and he acknowledged that the vitamin takers did visit the clinic more often than their counterparts. But anyone reading this report is likely to be among people with HIV who care about their health, and may therefore benefit by taking a daily multivitamin supplement with the B-complex vitamins in it.


Switching Protease Inhibitors

Presented by Pamela Bozek of the University of Maryland, Baltimore.

Bozek and her colleagues examined the questions of how long people stay on their initial protease inhibitor and if they change protease inhibitors, why. Bozek reviewed the treatment of 49 inner city patients who attended a university clinic. Ten of these patients were naïve to all antiretroviral therapy when they started their first protease inhibitor (PI). Most of these individuals had IV drug use as their risk factor for acquisition of HIV; more than half of the 49 were male.

Indinavir was the first choice PI for 25 (51 percent) of the study participants. Nelfinavir followed as the first choice of 14 (29 percent). Five (10 percent) selected saquinavir as the initial PI. One patient started on ritonavir, while four began with a combination of saquinavir and ritonavir.

At the end of 1 year, almost half of the patients, 49 percent, had dropped their first PI in favor of another. Of the 25 who started with indinavir, only 36 percent were still on it at the end of a year. Among the 64 percent who changed, most cited intolerance of the drug or an inability to adhere to it as the main reasons for switching. Data for the patients starting with nelfinavir were available for 6 months only, because of the drug's more recent introduction to market. Of the 14 who selected nelfinavir as their first PI, 86 percent were still on it at 6 months. The three who dropped it did so due to an adverse experience, intolerance, or lack of efficacy. The one patient who began with ritonavir stopped taking it because of intolerance. Four of the five who chose saquinavir as the initial PI abandoned it, with lack of efficacy as the most common reason given.

So what did patients switch to when they dropped the first PI? Of the 39 percent who rolled over to a new PI, more than half (57 percent) chose nelfinavir , with only 14 percent choosing indinavir. Of the remaining patients who dropped their first PI, 21 percent went to the dual combination of saquinavir/ritonavir as second-line PI therapy, and 29 percent took the opportunity to simply discontinue treatment. The rest selected some other form of treatment (for example, two nucelosides).

These data support the notes of caution heard in many quarters about the rigors and toxicity of PI-containing regimens. Moreover, the data underscore the importance of choosing a treatment regimen with careful attention to side effects and ease of use.


Viral Load Predictors

L.P. Jacobson of Johns Hopkins School of Public Health, Baltimore and colleagues sought to answer two questions.

Does viral load predict survival in severely immunosuppressed men and does antiretroviral therapy improve survival among these men if they are treatment naïve at the time therapy is started? The answer to both is yes.

The study involved 500 HIV-positive men whose CD4 cell count had fallen to 50 or below. For men in this group with viral loads of less than 100,000 copies, median survival was 2 years; for those with viral loads between 100,000 and 250,000, median survival was 1.9 years; and for those with viral loads above 250,000, median survival was 1.3 years. Interestingly, there was no difference in survival time between those with viral loads above 250,000 and those with viral loads above 500,000.

But for patients in each of these groups, antiretroviral therapy significantly delayed time to death. Among those with viral burdens above 250,000 copies, treatment delayed time to death by 2.04 years. Among those with viral loads between 100,000 and 250,000, it delayed time to death by 2.41 years. And for those with viral loads under 100,000, treatment delayed time to death by 1.26 years. The presenter explained the odd finding that survival time was shortest in those with the lowest viral load as a probable result of statistical difficulties, noting that the number of patients in the under 100,000 group was relatively small at 11.

Virtually everyone would agree that the patients in this study waited too long to start treatment. Nevertheless, this data supports previous findings that antiretroviral therapy provides a clinical benefit even for individuals with profound immune suppression.


What's That Mean?

The STEP Perspective often publishes updates on current scientific HIV/AIDS conferences to keep you informed of the most recent developments and breaking news. We realize that sometimes we use words and titles that are familiar to those who regularly attend these conferences but that might be new or strange to those of you who have never attended a conference. With that in mind, we have created this quick list of terms to help you understand the information, even if you've never been to a conference.

What is the 5th Conference on Retroviruses and Opportunistic Infections? A yearly meeting that was held in Chicago in 1998 and at which researchers, doctors and people living with HIV/AIDS (PWAs) share and discuss the latest information related to the treatment of HIV/AIDS and the other illnesses it can cause. The meeting is very small (fewer than 4,000 people) and it's difficult to get accepted to attend. Many doctors, PWAs, and treatment advocates apply each year but are not allowed to attend. The organizers of this conference wish to keep the numbers small, so that people actively working in this field can meet formally and informally to share information and ideas.

  • Opening Sessions: The opening sessions usually consist of two or three internationally known researchers presenting detailed lectures on subjects they are experts on. There is one presentation at each conference on the international issues currently needing attention. For example, this year Dr. Baltimore talked about the current status of an HIV vaccine.

  • State-of-the-Art Lectures: These lectures are also very detailed presentations by recognized leaders in a particular area of research. Unlike the opening sessions, these lectures generally are presented each morning and are the kick-off for the day's presentations. Usually no other presentations are given in any other room during the State-of-the-Art Lectures, so they are well attended.

  • Symposiums: These are usually panel discussions on one major topic. Several speakers may each present their research or summarize others' research and then discuss the information relevant to the topic. The session ends with questions asked to individual presenters or the panel as a whole.

  • Slide Sessions: This is how the majority of the sessions are presented. There usually are six to eight slide sessions going at one time so it is impossible to see them all -- you must pick and choose. Each session usually lasts about 2 hours and has a new presenter every 15 minutes. Presenters usually give a quick update on research they are conducting and then answer a few questions. The slide presentations are usually arranged so that all are on the same topic.

  • Poster Sessions: Poster studies are similar to the studies presented in the slide sessions except that the information is printed onto posters and displayed in a large hall. Researchers who submit posters usually stand by them during some portion of the Poster Session to answer questions. Often during the poster sessions you can see researchers, doctors, and PWAs sharing ideas and making plans to work on future projects.


Ask Dr. Jeff


QUESTION: My viral load has dropped to undetectable levels. Am I still at risk for HIV transmission?

Yes. Viral load tests (HIV RNA) measure the amount of HIV in the blood. All of the tests currently available have a certain level below which they cannot accurately measure the amount of HIV present. So, when your health care provider tells you that your viral load is "undetectable," what that really means is that the amount of HIV in the blood, or plasma, is below the detection limit for that viral load test. The most commonly used test for viral load has a detection limit of 500 copies of HIV per milliliter (ml) of blood.

So, based on the amount of blood that the average person has in their body, 5 liters, if you had 400 copies of HIV per ml of blood, you would have a "undetectable" viral load, but still have about 2,000,000 copies of HIV in your blood alone!

Additionally, it is known that most of the HIV resides in lymph nodes, not the blood. Newer viral load tests, which are not yet FDA approved, can detect as few as 20 to 50 copies of HIV per ml of blood. These tests are referred to as "ultrasensitive assays," and are used in most anti-HIV drug trials. They may be useful in deciding when to add or change drugs to a treatment regimen.

Secondly, it is still not known (and there are many studies ongoing), how closely the level of HIV in the blood, or plasma, correlates with the level of HIV in genital secretions. Some studies have shown a good correlation with plasma and genital secretion HIV levels, while others have not. Most studies have shown that when the level of HIV in plasma drops significantly, the level of HIV in genital secretions also decreases. Thus, a person may be (and probably is) less infectious when their viral load is undetectable, but they may still be able to transmit HIV via genital secretions.


QUESTION: What should I do if I am HIV-positive and have hepatitis C? What are my treatment options?

Co-infection with hepatitis C and HIV present some very serious treatment challenges because of the interactions of the different drugs used to treat each condition, and their effect on the other infection. Hepatitis C may become the next public health crisis after HIV. Recent estimates of the number of people in infected with hepatitis C in California are 500,000 and in Britain, 250,000, where it is estimated that the number of deaths from hepatitis C will exceed those due to HIV by the year 2000.

Before I discuss treatment specifics, you might need to know more about hepatitis C. Hepatitis C is primarily spread by blood-to-blood contact, either by transfusion or injection drug use. However, hepatitis C can also be spread by sexual contact. Since 1992, all blood products have been screened for hepatitis C. Hepatitis C is a silent, chronic viral infection causing ongoing hepatitis in up to 85 percent of all persons infected. It is usually diagnosed as part of an evaluation when someone has abnormal results on a liver function test.

It is recommended that all persons who received blood transfusions prior to 1992 get a test for hepatitis C. Many injection drug users are infected with hepatitis C, many more than are infected with HIV. With the increasing incidence of HIV infection among injection drug users, co-infection with HIV is becoming much more common.

Hepatitis C infection causes a chronic inflammation of the liver (hepatitis) which persists for decades, and some people progress to cirrhosis (hardening, or fibrosis, of the liver) and even liver cancer. Studies have shown the hepatitis C infection does not appear to affect survival of people infected with HIV.

Back to the treatment question. The major proven therapy for hepatitis C is alpha interferon injections. The initial recommended dose is 3 million units subcutaneous (needle injection beneath the skin), 3 times per week for 12 months. However, with alpha interferon therapy, only about 10 to 15 percent of people have sustained disappearance of the hepatitis C virus although more than 50 percent may have some transient benefit. (As with HIV, there are antibody tests for exposure to hepatitis C and for hepatitis C viral loads.) However, viral loads for hepatitis C do not correlate with the amount of liver damage present, and liver biopsy is recommended before being interferon therapy.

Recently, studies have shown better results when oral ribavirin is combined with interferon. People with CD4 counts above 200 have a better chance of benefiting from alpha interferon therapy. However, HIV viral levels increase significantly, and CD4 cells decrease, with alpha interferon therapy.

All of the approved protease inhibitors (PIs) cause significant, temporary worsening of liver function tests in most people who are co-infected with hepatitis C. Ritonavir metabolism is decreased in people with hepatitis, so a reduced dose of ritonavir should be considered for patients with both HIV and hepatitis. It is possible that the liver toxicity of the nonnucleoside reverse transcriptase inhibitors (NNRTIs) may be less.

Alcohol has been proven to accelerate the course of hepatitis C infection, so more than one drink per day is strongly discouraged and abstinence is recommended.


QUESTION: I have been on AZT, 3TC and saquinavir for several years without any side effects. My viral load is 3,000. Should I consider changing therapy, and if so, what should I try?

This is a difficult question. It would be important to know what your viral load was at the start of treatment, and how low it got, and for how long. But I'll assume you had a level significantly higher than 3,000 before treatment, and you have been stable at 3,000 for a while now. The underlying issue is how important is it to get your viral load below detection? All the major treatment guidelines recommend that you change therapy if it fails to lower your HIV RNA below 500, and you have some treatment options available. These recommendations are based on two factors.

First, it makes scientific sense that stopping HIV RNA replication significantly decreases the chance of drug resistance, and thus drug failure. This is because the virus can only become resistant if it is actually dividing, which is when a random mutation could occur. Random mutation is what allows the virus to develop resistance to the drugs you are on. Secondly, as noted in the above answer, the lower the HIV RNA at the start of treatment, the greater the chance that your viral load will stay at an undetected level for a longer period of time.

The really big unknown question is whether it is necessary for all people to get the viral load to an undetectable level (whether defined as below 500 or below 50). Most anti-HIV drug trials now define treatment failure in one of three ways: (1) failure to get to undetectable HIV RNA levels,whether at 500, 200, or even 20 copies per ml; (2) failure to reduce the level of HIV RNA by one-tenth; or (3) an increase in HIV RNA to a total of five times the lowest achieved level. The problem with using these strict criteria is that many people would run out of drugs before they ran out of virus.

At STEP's community forums, we have heard from many people in a similar situation who are maintaining levels of HIV RNA that are stable, low, but not below detection. The standard "party line" is that you should change therapy to get the HIV RNA lower. But that recommendation must be tempered by two critical items. First, what treatment options do you have available, and second, how committed are you to the goal of getting the HIV RNA to below detectable levels? If a person is not totally committed to the goals of therapy, then adherence may become a very large problem. With your specific treatment history, you have some good options. You could change to two new reverse transcriptase inhibitors (RTIs), such as d4T and ddI, and add either a non-nucleoside RTI (NNRTI), such as nevirapine, or a different protease inhibitor (PI). (The potent NNRTI, efavirenz, which is currently available in expanded access, should be approved by the FDA later this year.)

One of the advantages in selecting saquinavir as your first PI is that the chance of cross-resistance to other PIs is less with saquinavir than if you had chosen one of the other approved PIs, so switching to one of the other PIs now is a good option for you. Should you decide to change regimens at this time, you should have a thorough discussion of all options with your health care provider and make sure that he or she is very experienced in treating HIV.


Anna's Story


My name is Anna and I am a woman living with HIV/AIDS. I am a married mother of two boys and we live in Olympia, WA.

In 1994, when my partner and I were diagnosed with full-blown AIDS, there were no protease inhibitors, so we were placed on a mono-therapy of AZT. I would take many drug holidays, not understanding what I was doing to my body. Back then, I didn't feel sick, and I didn't totally understand that the therapy couldn't work unless I took my drugs as prescribed, whether or not I felt sick. AZT also meant a daily reminder of my disease -- that it was for real!

In 1995, my CD4 count started dropping fast and I was getting very sick. I quickly made the connection between the meds, HIV, and my health because I had immediate reactions and side effects from the AZT.

Being a parent and being sick did not go over well either. I remember my son often wanted me to drive him somewhere when I was lying on the couch with a horrible fever. Many times I would force myself into doing it, but there were also times when I had to say "Mommy is sick today." Funny how kids just don't understand mommy being sick most days.

Of course when I was taking drug holidays, I would feel good a lot more. But it was always the same when I went back to taking my meds. I'd feel sick and I would have to tell my sons, "Mom just took her medicine," hoping that they would understand. It didn't work with them though, because kids quickly see through things. They soon retorted, "If your medicine is making you so sick then why don't you stop taking it?" My children needed a mom and I wanted to be a mom again. And without a lot of support to take the meds, not to mention the disincentives of side effects, I stopped. After stopping I became sick off and on, but it was better than being sick all of the time.

In August of 1997 I started the protease inhibitor Viracept. It hasn't been easy. I take it three times a day and sometimes I forget the afternoon dose. Also, I have a very hard time taking it in the morning because it gives me a stomachache, so I take it later in the morning or at least try to take it by noon. Many times I forget my evening dose because I fall asleep if I have to stay up until midnight or later to take it at the right interval. Taking this medicine is hard, but I know that if I want to be alive to see my children graduate and to be a grandma someday, then I have to take this medicine no matter how hard it gets. Even though I've missed doses of my Viracept, lab tests indicate it is still working. So far so good.

Living in Olympia I felt alone, like I was the only woman in town with this disease. I got a lot of support from all of the wonderful gay men I met at what was then called the Olympia AIDS Task Force, and is now known as the United Communities AIDS Network (UCAN). I attended their support group every week, but felt I needed another woman to talk with, someone who could identify with having kids.

Living with HIV and being a full time mom and housewife is and was not easy. I had no one to talk to who could understand what I was feeling, so I put together a support group with a wonderful friend of mine. Together we made it happen. Today I am the president of Positive Friends of Washington, a support group for women living with HIV.

Our group got a lot of support from our local health department, from our case manager Deb Sentella, and from our local AIDS service organization UCAN. With the help of Executive Director Kevin Corbin and the Client Service Manager Miranda Craig, we have built the group until we now have seven women who come, and we are all very good friends. I'm hoping that more women in our community will find out that we are here. We want them to know that they are not alone in Olympia and that what we share is something that only other women living with HIV can understand.

Sincerely, Anna B.


Pregnant Pause


Every day, you take protease inhibitors to keep your viral load in check and your CD4 count as high as possible. You take the pills diligently, every 8 hours, 12 hours, 4 hours, or however often your healthcare provider has told you to. Once a day you take a birth control pill to keep you from getting pregnant, reduce cramping during your periods, and/or regulate your cycle. Your viral load is low and you haven't gotten pregnant, so everything is fine, right? Maybe.

While various anti-HIV drugs, from AZT to protease inhibitors, have been evolving, little research has been done on the interaction of these drugs with birth control pills. The research that has been done on pharmaceutical interaction is not widely published, and with so many anti-HIV drugs in use, women are bound to become confused.

The level of interaction between anti-HIV drugs and birth control pills depends on which drugs you are taking. If you are on the protease inhibitors Norvir (ritonavir) or Viracept (nelfinavir), the level of contraceptive in your system may be lowered, causing the contraceptive to work less effectively. In a study conducted by Abbott, women who were taking oral contraceptives added ritonavir into their medication regimen. After the introduction of ritonavir, the amount of contraceptive in their bodies was lowered by up to 40%. Nelfinavir has been shown to reduce the level of contraceptive in women's bodies from 18% to 47%. While studies on Crixivan (indinavir) are limited, those that have been done show a decrease in oral contraceptive levels between 14% and 17%. The protease inhibitor Invirase (saquinavir) has not shown the same result, but it has not been studied thoroughly.

So why do these drugs act this way? The purpose of taking birth control pills is to maintain a level of hormones in your system so that you will not get pregnant, your period will come on time, and you will experience less painful menstruation. These hormones are metabolized gradually by your body throughout the day and after 24 hours they need to be replaced. That's when you take another birth control pill. When you start taking protease inhibitors, the protease inhibitors speed up the process by which hormones are metabolized. The hormones are metabolized up to twice as fast and therefore you have less of the contraceptive in your system. This can lead to being twice as likely to get pregnant, having an irregular period, or experiencing more cramping.

Other drugs commonly used by HIV-positive women can affect blood levels of oral contraceptives as well. Rifabutin, a preventative treatment for Mycobacterium (MAC) has been shown to decrease blood levels of birth control medications as a result of its effect on liver enzyme production.

For HIV-positive women -- and men -- using steroids or testosterone hormone replacement therapy to increase energy levels, manage depression, or gain weight, antiviral drugs can have the same decreasing effect on those therapies. Drugs that are not specific to the treatment of HIV, but that are commonly used in HIV management, may be similarly affected by oral contraceptives. These include acetaminophen, benzodiazepines, theophyllin, and some antidepressants.

We will soon have more information about the interaction of birth control pills and anti-HIV drugs. Roxane Laboratory is currently enrolling HIV-positive women in New York City and San Francisco to study the interaction of anti-HIV drugs and oral contraceptives.

A study by Boehringer Ingelheim Pharmaceuticals on the interaction of Viramune (nevirapine), a non-nucleoside reverse transcriptase inhibitor, and Ortho-Novum was recently completed, but the results have not yet been released. Here in Seattle, the University of Washington's AIDS Clinical Trials Unit is recruiting women to participate in a study on the effects of an AZT/Crixivan (indinavir) combination on oral and injectable contraceptives. If you are interested in participating in this study, contact the screening nurse, Karen Novak, at (206) 731-0206.

In summary, if you are taking both antiretroviral drugs and birth control pills you should talk with your provider about your options for increasing the birth control dosage and/or other means of preventing pregnancy, reducing cramping, or regulating your period. As a common sense precaution, however, never increase or "double up" birth control pills unless under the supervision of your provider. Doing so can be dangerous to your health. If you are wondering what other drugs might alter the effectiveness of your birth control, consult the package insert of both drugs, and then talk to your provider about your options.


Muscle Madness


Rock hard abs, bulging biceps, toned muscular legs, and a broad powerful back are what the media say we should all look like. But for people living with HIV/AIDS, a strong muscular body is about much more than vanity.

The loss of body cell mass is a strong indicator of wasting and has been closely tied to disease progression. And the loss of body cell mass has been shown to be a strong predictor of disease progression and death. Bioelectrical impedance analysis (BIA) is a test that measures your body's cell mass, the metabolically important tissue contained in your muscles and organs. It can tell you, with reasonable accuracy, how much muscle and fat you have in your body. It will also tell you if you are well hydrated (have enough water in your body) and whether your cells appear healthy.

Why have your muscle mass measured? Many studies have shown that individuals living with HIV/AIDS who maintain their muscle mass within a normal level have a greater chance of suppressing viral replication, supporting the immune system, avoiding opportunistic infections, and enjoying a greater sense of well-being and energy.

Wasting remains a risk for people living with the virus because as the virus replicates, the body increases its rate of metabolism and thereby burns more calories, protein, and overall energy, which often leads to weight loss and smaller muscles. The metabolisms of people with HIV/AIDS burn calories at a rate 10 to 35 percent higher than normal, which ultimately destroys muscle tissue and lean body mass. Especially if you are on protease therapy, maintaining your muscle mass is essential to supporting your immune system and may offset the tendency to gain a lot of weight around your gut (a condition sometimes called "protease paunch").

By having a BIA test done at 6-month intervals, you will see if you are gaining, losing, or maintaining your essential muscle. Although one measurement will give you an idea of how you are doing, a more accurate way to assess your body is to have BIA measurements performed every 6 months. The BIA measurements are most accurate when trends are observed over time.


How is it done?

To have a BIA test, all you need to do is to remove one shoe and sock so an electrode can be attached to your foot. Another is attached to your hand. A painless electrical current is passed through your body and the speed of the current is measured. The faster the current travels from your hand to your foot, the more water is in your body. Muscle has more water than fat and therefore a faster current indicates more muscle is present and a slower current indicates more fat is present. The BIA machine is hooked up to a computer that can analyze the results and determine your hydration status, percentage of muscle, and fat mass.


How do I prepare for this test?

Be sure that you have been drinking enough water during the 24 hours before the test. If you are dehydrated, your test results will be inaccurate. You need to drink at least 10 cups of water or juice each day. For each cup of coffee, alcohol, or caffeinated beverage, be sure to drink 2 cups of water. Also, do not exercise strenuously within 12 hours of your scheduled test. This too can make you appear dehydrated and may make your results inaccurate.

Avoid eating too much salty food such as chips and pretzels the day of your test since salt can also dehydrate your body. On the day of your test, do not put lotion on the hand and foot to be tested because the electrodes won't stick.


What results do I get?

Results of this test will look like this:

  • Fluid Assessment (Total Body Water): Goal for Men: 55 to 60% of total body weight. Goal for Women: 50 to 60% of total body weight. For example, if you weigh 150 pounds, about 90 pounds should consist of water. As muscle mass increases, so does the water level in your body. As wasting occurs, your body is composed of less water.

  • Nutrition Assessment: This section will tell you two things: your body cell mass (muscle) and your fat mass.

  • Body Cell Mass (Muscles and Organs): Goal for Men: 40 to 45% of ideal weight. If you weigh 150 pounds, ideally 60 to 70 pounds should be muscle. Goal for Women: 30 to 35% of ideal weight. If you weigh 130 pounds, ideally 40 to 45 pounds should be muscle.

  • Fat Mass (Body Fat Measure): Goal for Men: 10 to 20% of body weight. If you weigh 150 pounds, 15 to 30 pounds should be fat. Goal for Women: 20 to 30% of body weight. If you weigh 130 pounds, 26 to 40 pounds should be fat.

  • Phase Angle (Cellular Health Measure): This term is used to describe changes in electrical conductivity in the body and is a measure of how healthy your cells appear. This number changes as muscle mass, water content, or fat mass changes.

    • Goal for Men: Phase angle of 6 or more.
    • Goal for Women: Phase angle of 5 or more. A phase angle of 4.8 or less has been associated with an increase in Illness and death in HIV-positive males.


Questions?

Call Sabina the dietitian at Chicken Soup Brigade at 206-320-0213.




This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art1799.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.